The management of the hyperlipidaemias

  • N. I. Jowett
  • D. J. Galton


The hyperlipidaemias are a common and heterogeneous group of metabolic disorders which affect more than 10% of the population of Western industrialized countries [1–3]. Although hypertension and diabetes mellitus are well established as predisposing factors for the development of atherosclerotic disease [4, 5] the role of dietary fat and altered lipoprotein metabolism is not so well understood [6–8]. Epidemiological studies have demonstrated that increased levels of plasma cholesterol may be associated with premature coronary heart disease [2, 3] and the United States Lipid Research Clinics trial [9] has given clear evidence that reducing high cholesterol levels in men will lower the incidence of coronary heart disease (CHD), and additionally will significantly reduce deaths, myocardial infarcts, angina and the need for coronary artery bypass surgery. These results confirm previous similar reports [10–12].


Coronary Heart Disease Bile Acid Nicotinic Acid Familial Hypercholesterolaemia Bile Acid Sequestrant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Carlson, L.A. and Linstedt, S. (1969) The Stockholm Prospective Study. The initial values for plasma lipids. Acta Med. Scand., Suppl., 493.Google Scholar
  2. 2.
    Kannel, W.B., Castelli, W.P., Gordon, T. et al. (1971) Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann. Intern. Med., 74, 1.PubMedCrossRefGoogle Scholar
  3. 3.
    Fuller, J.H., Pinney, S., Jarrett, R.J. et al. (1978) Plasma lipids in a London population and their relation to other risk factors for coronary heart disease. Br. Heart J., 40, 170.PubMedCrossRefGoogle Scholar
  4. 4.
    Marks, H.H., Krall, L.P. and White, P. (1971) Epidemiology and detection of diabetes mellitus. In Joslin’s Diabetes Mellitus (ed. Marble, White, Bradley and Krall), Lea and Febiger, Philadelphia.Google Scholar
  5. 5.
    Walker, W.J. (1976) Success story: the Program against major cardiovascular risk factors. Geriatrics, 31, 97.PubMedGoogle Scholar
  6. 6.
    Walker, A.R.P. (1978) Diet and coronary heart disease. S. Afr. Med. J., 53, 587.PubMedGoogle Scholar
  7. 7.
    Mann, G.V. et al. (1978) Diet-heart era: premature obituary? N. Engl. J. Med., 298, 106–8.CrossRefGoogle Scholar
  8. 8.
    Ahrens, E.H. (1979) Dietary fats and coronary heart disease: unfinished business. Lancet, 2, 1345.PubMedCrossRefGoogle Scholar
  9. 9.
    The Lipid Research Clinics coronary primary prevention trial results (1984) J. Am. Med. Assoc., 251, 351.CrossRefGoogle Scholar
  10. 10.
    Dayton, S., Pearce, M.L., Hashimoto, S. et al. (1969) A controlled trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation, 40, (Suppl. 2), 1.Google Scholar
  11. 11.
    Hjermann, I., Byre, K.V., Holme, I. et al. (1981) Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo study group of a randomised trial in healthy men. Lancet, 2, 1303.PubMedCrossRefGoogle Scholar
  12. 12.
    WHO Clofibrate Trial Committee of Principal Investigators (1978) A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J., 40, 1069.CrossRefGoogle Scholar
  13. 13.
    Carlson, L.A. and Bottiger, L.E. (1972) Ischaemic heart disease in relation to fasting values of plasma triglycerides and cholesterol: Stockholm Prospective Study. Lancet, 1, 865.PubMedCrossRefGoogle Scholar
  14. 14.
    Carlson, L.A., Bottiger, L.E. and Ahfeldt, P.E. (1979) Risk factors for myocardial infarction in the Stockholm Prospective Study: A 14 year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Med. Scand., 206, 351.PubMedCrossRefGoogle Scholar
  15. 15.
    Hulley, S.B., Rosenman, R.H., Bawol, R.D. et al. (1980) Epidemiology as a guide to clinical decisions: The association between triglyceride and coronary heart disease. N. Engl. J. Med., 382, 1383.CrossRefGoogle Scholar
  16. 16.
    Chivers, A.G., Lea Thomas, M. and Browse, N.L. (1974) The Progression of arteriosclerosis. A radiological study. Circulation, 50, 402.CrossRefGoogle Scholar
  17. 17.
    Gensini, G.G., Esente, P. and Kelly, A. (1974) Natural history of coronary disease in patients with and without coronary bypass graft surgery. Circulation, 50, 98.Google Scholar
  18. 18.
    Duffield, R.G.M., Lewis, B., Miller, N.E. et al. (1983) Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. Lancet, 2, 639.PubMedCrossRefGoogle Scholar
  19. 19.
    Galton, D.J., Stocks, J. and Dodson, P.M. (1982) Lipoproteins - their role in enzyme regulation. In Clinical Biochemistry Review, Vol. 3. (ed. D.M. Golberg) Wiley, New York.Google Scholar
  20. 20.
    Beaumont, J.L., Carlson, L.A., C000per, G.R. et al. (1970) Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull. Wld. Hlth, Org., 43, 891.Google Scholar
  21. 21.
    Fredrickson, D.S., Goldstein, J.L. and Brown, M.S. (1983) in The Metabolic Basis of Inherited Disease, 5th edn, (eds J.B. Stanbury, J.B. Wyngaarden, & D.S. Fredrickson). McGraw-Hill, New York.Google Scholar
  22. 22.
    Lewis, B., Chait, A., Wootton, I.D.P. et al. (1974) Frequency of risk factors in a healthy British population. Lancet, i, 141.Google Scholar
  23. 23.
    Tall, A.R. and Small, D.M. (1978) Current concepts. Plasma high density lipoproteins. N. Engl. J. Med., 299, 1232.PubMedCrossRefGoogle Scholar
  24. 24.
    Gordon, T. (1980) HDL and coronary heart disease (letter). Lancet, 2, 1139.CrossRefGoogle Scholar
  25. 25.
    Durstine, J.L., Miller, W., Farrell, W.M. and Ivy, J.L. (1983) Increases in HDL-cholesterol and the HDL/LDL cholesterol ratio during prolonged endurance exercise. Metabolism, 32, 10.CrossRefGoogle Scholar
  26. 26.
    Morris, J.N., Everitt, M.G. and Pollard, R. (1980) Vigorous exercise in leisure-time: Protection against coronary heart disease. Lancet, 2, 1207.PubMedCrossRefGoogle Scholar
  27. 27.
    Schlierf, G., Chwat, M., Feverborn, et al. (1980) Bezafibrate and clofibrate in hyperlipidaemia. Atherosclerosis, 36, 323.CrossRefGoogle Scholar
  28. 28.
    Coronary Project Group (1975) Clofibrate and niacin in coronary heart disease. J. Am. Med. Assoc., 231, 360.CrossRefGoogle Scholar
  29. 29.
    Committee of Principal Investigators (1980) WHO cooperative trial on the prevention of ischaemic heart disease using clofibrate to lower serum cholesterol. Mortality follow-up. Lancet, 11, 379.Google Scholar
  30. 30.
    Keen, H., Lewis, B., Miller, N.E. et al. (1980) Clofibrate and hyperlipidaemia. Lancet, 2, 1241.PubMedCrossRefGoogle Scholar
  31. 31.
    Lelorier, J., Dubrenil-Quidoz, S., Lussier-Cacan, S. et al. (1977) Diet and probucol in lowering cholesterol concentrations. Arch. Intern. Med., 137, 1429.PubMedCrossRefGoogle Scholar
  32. 32.
    Shepherd, J., Packard, C.J., Patsch, J.R. et al. (1979) Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and apoprotein A metabolism. J. Clin. Invest., 63, 858.PubMedCrossRefGoogle Scholar
  33. 33.
    Kane, J.P., Malloy, M.J., Tun, P. et al. (1981) Normalization of low-densitylipoprotein levels in heterozygous familial hypercholesterolaemia with a combined drug regimen. N. Engl. J. Med., 304, 251.PubMedCrossRefGoogle Scholar
  34. 34.
    Witztum, J.L., Schonfield, D. and Weidman, S.W. (1976) The effect of colestipol on the metabolism of very low density lipoproteins in man. J. Lab. Clin. Med., 88, 108.Google Scholar
  35. 35.
    Hashim, S.A. and Italie, T.B. (1965) Cholestyramine resin therapy for hypercholesterolaemia. J. Am. Med. Assoc., 192, 289.CrossRefGoogle Scholar
  36. 36.
    Levy, R.L., Fredrickson, D.S., Kwiterovich, P.O. et al. (1969) Normalisation of lipids in familial hypercholesterolaemia. Circulation, 40, (Suppl.3), 15.Google Scholar
  37. 37.
    Glueck, C.J., Ford, S. Scheel, D, et al. (1972) Colestipol and cholestyramine resin. J. Am. Med. Assoc., 222, 676.CrossRefGoogle Scholar
  38. 38.
    Buchwald, H., Moore, R.B. and Varco, R.L. (1981) in Atherosclerosis V (eds A.M. Gotto et al.), Springer-Verlag, Berlin, pp. 462–5.Google Scholar
  39. 39.
    Chalstrey, L.J., Winder, A.F. and Galton, D.J. (1982) Partial ileal bypass in the treatment of familial hypercholesterolaemia. J. Roy. Soc Med., 75, 851–6.PubMedGoogle Scholar
  40. 40.
    Thompson, G.R., Lowenthal, R. and Myant, N.B. (1975) Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet, 2, 1208.CrossRefGoogle Scholar
  41. 41.
    Brook, G., Winterstein, G. and Aviram, M. (1983) Platelet function and lipoprotein levels after plasma-exchange in patients with familial hypercholesterolaemia. Clin. Sci., 64, 637.PubMedGoogle Scholar
  42. 42.
    Lerne, P., Foss, P.O., Helgeland, A. et al. (1980) Effect of propranolol and Prazosin on blood lipids. The Oslo Study. Lancet, 2, 4.CrossRefGoogle Scholar
  43. 43.
    Grimm, R.H., Leon, A.S., Hunninghake, D.B. et al. (1965) Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. A double-blind controlled trial. Ann. Intern. Med., 94, 7.CrossRefGoogle Scholar
  44. 44.
    Samuel, P. (1980) Drug treatment of hyperlipidaemia. Am. Heart J., 100, 573.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1987

Authors and Affiliations

  • N. I. Jowett
  • D. J. Galton

There are no affiliations available

Personalised recommendations